Evidence map›Paper›PMID 39703112›Full record

ArticleDiabetes, obesity & metabolism2025

Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real-world setting in China.

Lixin Guo, Liming Chen, Fan Zhao, Xiaoyun Liu, Hongcheng Ding, Kun Wang, Xing Zhong, Vinay Babu Shankarappa, Gaurav Chaudhary

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lixin GuoDepartment of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.ORCID 0000-0001-6863-1798
Liming ChenChu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.ORCID 0000-0002-5682-2340
Fan ZhaoThe People's Hospital of Jiangmen, Jiangmen, China.
Xiaoyun LiuThe Second Hospital of Chifeng, Chifeng, China.
Hongcheng DingHubei University of Medicine, Shiyan, China.
Kun WangEndocrinology Department, Jiangning Hospital affiliated to Nanjing Medical University, Nanjing, China.
Xing ZhongNovo Nordisk (Shanghai) Pharma Trading Co. Ltd, Shanghai, China.
Vinay Babu ShankarappaNovo Nordisk Denmark A/S, Copenhagen, Denmark.
Gaurav ChaudharyNovo Nordisk India Private Limited, Bangalore, India.

Funding

Novo Nordisk
6 · The paper itself

Abstract

aimsTo investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co-formulation of basal, and bolus insulin, in a real-world setting. MATERIALS AND

methodsA 20-week, prospective, single-arm, open-label, non-interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti-hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon-like peptide-1 receptor agonists. The primary endpoint was a change in HbA

resultsSignificant reductions were observed in mean HbA

conclusionsIn a broad, real-world Chinese population of adults with T2D, initiating or switching to IDegAsp was associated with improved glycaemic control and lower rates of hypoglycaemia. The use of IDegAsp could be an effective treatment option for those with suboptimal glycaemic control or therapeutic inertia.

Indexed as

Diabetes Mellitus, Type 2Glycemic ControlHypoglycemic AgentsInsulin, Long-ActingAdultAgedBlood GlucoseChinaDrug CombinationsDrug SubstitutionFemaleGlycated HemoglobinHumansHypoglycemiaMaleMiddle AgedBlood GlucoseDrug CombinationsGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsinsulin degludec, insulin aspart drug combinationInsulin, Long-ActingChinafasting plasma glucoseglycaemic controlhaemoglobin A1c (HbA1c)hypoglycaemiainsulin analoguestype 2 diabetes

Identifiers

PMID39703112
PMCPMC11802397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.